Jeevan Scientific Technology Limited Shareholders Approve Key Resolutions in EGM

Jeevan Scientific Technology Limited (JSTL) held a successful Extraordinary General Meeting (EGM) on November 12, 2025, where shareholders approved four significant resolutions, paving the way for potential growth and structural changes within the company.

Meeting Details

The EGM, conducted through video conferencing from 10:00 AM to 10:40 AM, saw the participation of 58 members out of a total of 5,436 shareholders on the record date. The meeting was chaired by Mr. Divakar Atluri, with key management personnel, including Managing Director K. Krishna Kishore and Company Secretary Krishna Sainadh Kodati, in attendance.

Approved Resolutions

The shareholders passed the following resolutions with the requisite majority:

Adoption of New Memorandum of Association: A special resolution to adopt a new Memorandum of Association in compliance with the Companies Act, 2013.
Increase in Authorized Share Capital: An ordinary resolution to increase the authorized share capital from Rs. 21 crore to Rs. 25 crore, divided into 2.5 crore equity shares of Rs. 10 each.
Issue of Convertible Warrants: A special resolution to approve the issuance of convertible warrants on a preferential basis to promoters and non-promoters for cash consideration.
Issue of Equity Shares: A special resolution to approve the issuance of equity shares on a preferential basis to non-promoters for cash consideration.

Voting Results

The voting process included remote e-voting from November 9-11, 2025, and electronic voting during the meeting. Here's a summary of the voting results:

Resolution	Type	Votes in Favor (%)	Votes Against (%)	Result
Adoption of New MOA	Special	99.99	0.01	Passed
Increase in Authorized Capital	Ordinary	99.73	0.27	Passed
Issue of Convertible Warrants	Special	99.27	0.73	Passed
Issue of Equity Shares	Special	99.73	0.27	Passed

Implications

These resolutions suggest that Jeevan Scientific Technology Limited may be preparing for expansion or significant corporate actions. The increase in authorized share capital and approval for issuing convertible warrants and equity shares could indicate plans for raising funds, potentially for growth initiatives or strengthening the company's financial position.

The adoption of a new Memorandum of Association aligns the company with the latest regulatory requirements, which may enhance corporate governance practices.

Investors and stakeholders will likely be watching closely to see how JSTL utilizes these approvals to drive future growth and create value for shareholders.

As the company moves forward with these resolutions, it will be crucial to monitor how effectively management implements these changes and the impact on JSTL's financial performance and market position in the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.03%	-0.05%	+18.61%	+53.00%	+20.13%	+91.04%

Jeevan Scientific Technology Limited , a company specializing in clinical research and data management services, has reported a net loss for the quarter and half year ended September 30, according to its recently released unaudited financial results.

Financial Performance

The company's consolidated financial statements reveal a significant downturn in profitability compared to the previous fiscal year. For the half year ended September 30, Jeevan Scientific Technology reported a consolidated net loss before tax of ₹369.90 lakhs, a stark contrast to the profit of ₹5.07 lakhs recorded for the year ended March 31.

On a standalone basis, the company's performance showed a similar trend:

Particulars	Half Year Ended Sept 30	Year Ended March 31
Net Profit/(Loss) before tax	(₹268.56)	₹77.05
Cash and cash equivalents	₹77.42	₹20.59

Operational Highlights

Despite the challenging financial results, the company has maintained its operational activities. The cash flow statement indicates some positive movements:

Net cash from operating activities stood at ₹53.76 lakhs for the half year ended September 30.
The company saw an increase in cash and cash equivalents, rising from ₹20.59 lakhs at the beginning of the period to ₹77.42 lakhs by the end of September.

Balance Sheet Overview

As of September 30, Jeevan Scientific Technology's consolidated balance sheet showed:

Total assets of ₹8,380.67 lakhs, up from ₹7,825.05 lakhs as of March 31.
Total equity (including non-controlling interest) decreased to ₹4,722.01 lakhs from ₹5,007.12 lakhs.
Current liabilities increased significantly to ₹7,345.27 lakhs from ₹1,207.05 lakhs, indicating a substantial rise in short-term obligations.

Subsidiary Performance

The company's subsidiary, Nayas Laboratories Private Limited, contributed positively to the group's results:

Total revenues of ₹194.18 lakhs for the quarter ended September 30.
Net profit after tax of ₹9.50 lakhs for the same quarter.

Auditor's Review

The independent auditor, Pavuluri & Co., conducted a review of the financial results. They stated that nothing has come to their attention that causes them to believe that the financial statements do not present a true and fair view in accordance with applicable accounting standards and other recognized accounting practices and policies.

Looking Ahead

While the company faces challenges in the current financial landscape, the increase in cash and cash equivalents and the positive contribution from its subsidiary may provide some stability. However, the significant rise in current liabilities and the overall net loss position suggest that Jeevan Scientific Technology may need to focus on cost management and revenue growth strategies in the coming quarters to improve its financial health.